Promis Neurosciences Inc (PMN) — Who's Buying and Selling (13F, Q2 2026)

PMN ranks #7734 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PMN is a top-conviction position for Ally Bridge Group — at 7.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PMN belongs to Jupiter Topco LLC, but the position matters far more to Ally Bridge Group, who has 7.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

PMN is down 6.3% today, but institutions show net buying of $4.9M this quarter — a divergence between today's price move and the underlying institutional flow.

PMN reported a net loss of $39.7M in its latest fiscal year.

• Not yet profitable — net loss of $39.7M in the latest fiscal year
• Net income declined year over year, from $2.8M to -$39.7M
• Operating cash flow was negative, using $28.1M in cash
• Current ratio of 0.88x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)